Jpmorgan Chase & CO E Ffector Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024
BUY
$0.37 - $0.69 $14 - $26
38 Added 126.67%
68 $0
Q3 2023

Nov 14, 2023
BUY
$0.49 - $0.88 $14 - $26
30 New
30 $0
Q1 2022

May 11, 2022
SELL
$3.85 - $8.2 $3,003 - $6,395
-780 Closed
0 $0
Q4 2021

Feb 10, 2022
BUY
$5.71 - $13.15 $4,453 - $10,257
780 New
780 $6,000

Others Institutions Holding EFTR

# of Institutions
5
Shares Held
6.46M
Call Options Held
0
Put Options Held
0
View Full List

About eFFECTOR Therapeutics, Inc.

EFTR Quotes by TradingView
  • Ticker EFTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,452,800
  • Description
  • eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...
More about EFTR
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email